Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2017 1
2019 3
2020 6
2021 7
2022 9
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Epigenetic remodelling in human hepatocellular carcinoma.
Braghini MR, Lo Re O, Romito I, Fernandez-Barrena MG, Barbaro B, Pomella S, Rota R, Vinciguerra M, Avila MA, Alisi A. Braghini MR, et al. Among authors: pomella s. J Exp Clin Cancer Res. 2022 Mar 24;41(1):107. doi: 10.1186/s13046-022-02297-2. J Exp Clin Cancer Res. 2022. PMID: 35331312 Free PMC article. Review.
FAK Signaling in Rhabdomyosarcoma.
Perrone C, Pomella S, Cassandri M, Braghini MR, Pezzella M, Locatelli F, Rota R. Perrone C, et al. Among authors: pomella s. Int J Mol Sci. 2020 Nov 10;21(22):8422. doi: 10.3390/ijms21228422. Int J Mol Sci. 2020. PMID: 33182556 Free PMC article. Review.
Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma.
Pomella S, Porrazzo A, Cassandri M, Camero S, Codenotti S, Milazzo L, Vulcano F, Barillari G, Cenci G, Marchese C, Fanzani A, Megiorni F, Rota R, Marampon F. Pomella S, et al. Int J Mol Sci. 2022 Oct 31;23(21):13281. doi: 10.3390/ijms232113281. Int J Mol Sci. 2022. PMID: 36362070 Free PMC article. Review.
Radioresistance in rhabdomyosarcomas: Much more than a question of dose.
Camero S, Cassandri M, Pomella S, Milazzo L, Vulcano F, Porrazzo A, Barillari G, Marchese C, Codenotti S, Tomaciello M, Rota R, Fanzani A, Megiorni F, Marampon F. Camero S, et al. Among authors: pomella s. Front Oncol. 2022 Sep 29;12:1016894. doi: 10.3389/fonc.2022.1016894. eCollection 2022. Front Oncol. 2022. PMID: 36248991 Free PMC article. Review.
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Pomella S, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. Pomella S, et al. Nat Commun. 2023 Dec 15;14(1):8373. doi: 10.1038/s41467-023-44130-0. Nat Commun. 2023. PMID: 38102140 Free PMC article.
KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY, Gryder BE, Sinniah R, Peach ML, Shern JF, Abdelmaksoud A, Pomella S, Woldemichael GM, Stanton BZ, Milewski D, Barchi JJ Jr, Schneekloth JS Jr, Chari R, Kowalczyk JT, Shenoy SR, Evans JR, Song YK, Wang C, Wen X, Chou HC, Gangalapudi V, Esposito D, Jones J, Procter L, O'Neill M, Jenkins LM, Tarasova NI, Wei JS, McMahon JB, O'Keefe BR, Hawley RG, Khan J. Kim YY, et al. Among authors: pomella s. Nat Commun. 2024 Feb 24;15(1):1703. doi: 10.1038/s41467-024-45902-y. Nat Commun. 2024. PMID: 38402212 Free PMC article.
34 results